Denali Therapeutics Current Ratio 2016-2021 | DNLI

Current and historical current ratio for Denali Therapeutics (DNLI) from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Denali Therapeutics current ratio for the three months ending June 30, 2021 was 26.10.
Denali Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.34B $0.05B 26.10
2021-03-31 $1.43B $0.06B 26.22
2020-12-31 $1.50B $0.07B 20.86
2020-09-30 $0.97B $0.11B 9.21
2020-06-30 $0.56B $0.06B 9.57
2020-03-31 $0.61B $0.05B 12.70
2019-12-31 $0.43B $0.05B 9.48
2019-09-30 $0.49B $0.05B 10.59
2019-06-30 $0.50B $0.05B 10.66
2019-03-31 $0.50B $0.04B 11.55
2018-12-31 $0.48B $0.03B 14.67
2018-09-30 $0.38B $0.03B 12.13
2018-06-30 $0.38B $0.03B 12.17
2018-03-31 $0.38B $0.02B 21.99
2017-12-31 $0.41B $0.01B 28.92
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.18B $0.01B 19.98
2015-12-31 $0.03B $0.00B 9.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.814B $0.336B
Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76